

Please complete all required sections to allow your request to be

PEGINTERFERON ALFA-2A for Chronic Hepatitis C SPECIAL AUTHORIZATION REQUEST FORM

Patients may or may not meet eligibility requirements as established by

PATIENT INFORMATION				COVERAGE TYPE:	
PATIENT LAST NAME	FIRST NAME		INITIAL Alberta Blue Cross Alberta Human Services		
DATE OF BIRTH: Year / Month / Day	ALBERTA PERSONA	AL HEALTH NUMBER	3	Other	
STREET ADDRESS	CITY	PROV	POSTAL CODE	IDENTIFICATION/CLIENT/COVERAGE No:	
NOTIFICATION:		PATIENT CONS	SENT:		
You may be eligible to receive Pegasys drug benefits. Information from your prescriber is required to determine eligibility. Your consent is required: (A) for your prescriber to release necessary and relevant information to Alberta Blue Cross, Alberta Health and, if requested, to Alberta Human Services; and (B) for Alberta Blue Cross to release that and related usage information to Alberta Health.		I hereby authorize: (A) my prescriber to release to Alberta Blue Cross, Alberta Health, and (if they request it) to Alberta Human Services (the aforesaid being the "designated recipients"); and (B) Alberta Blue Cross to release to Alberta Health the information on this form and information relating to my usage of and experience with the drug and treatment results, and I consent to the designated recipients collecting such information. Date Patient's Signature			
PRESCRIBER INFORMATION					
PRESCRIBER LAST NAME FIRST NAME INITIAL		PRESCRIBER F	PRESCRIBER PROFESSIONAL ASSOCIATION REGISTRATION ☐ CPSA ☐ ACO REGISTRATION NO.		
STREET ADDRESS		☐ CARNA ☐ ACP	☐ ADA+C ☐ Other	Leav	
CITY, PROVINCE		PHONE:		FAX:	
POSTAL CODE		FAX NUMBER MUST BE PROVIDED WITH EACH REQUEST SUBMITTED			
Diagnosis of chronic hepatitis C: Is the patient serum HCV RNA positive (by PCR), pre-treatment					
Evidence of active liver disease:					
At least one of the following: a) does the patient have elevated liver enzymes (ALT and/or AST), pre-treatment					
INITIAL REQUEST: EXTENSION REQUEST:					
Demonstrative treatment outer size at 44 weeks (overlyding petition)				11 weeks (excluding nationts with	
	ac	vanced fibrosis and cirrhosis): the patient serum HCV RNA negative at 12 weeks?			
Initial length of approval: Advanced fibrosis or cirrhosis (regardless of genotype)48 weeks Genotype 1					
PREVIOUS THERAPY: Consideration may be given to patients who have previously received therapy and who meet at least one of the following:					
Advanced fibrosis or cirrhosis. Patient relapsed following non-pegylated interferon/ribavirin combination therapy.					
Additional information relating to request:					
	ATE	Please forward this request to: • Alberta Blue Cross, Clinical Drug Services 10009-108 Street NW, Edmonton, Alberta T5J 3C5 • FAX: 780-498-8384 in Edmonton • 1-877-828-4106 toll free all other areas			
ONCE YOUR REQUEST HAS SUCCESSFULLY TRANSMITTED, PLEASE DO NOT MAIL OR RE-FAX YOUR REQUEST.					

The information collected by this form is collected pursuant to sections 20, 21 and 22 of the Health Information Act, and sections 33 and 34 of the Freedom of Information and Protection of Privacy Act, for the purpose of determining or verifying eligibility to participate in a program or receive a benefit, product or health service. If you have any questions regarding the collection or use of this information, please contact an Alberta Blue Cross privacy matters representative toll-free at 1-855-498-7302 or write to Privacy Matters, Alberta Blue Cross, 10009 - 108 Street, Edmonton AB TSJ3CS.

ABC 30944 (2014/02) ®The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan.